MET and neoplasm: Consistent with the in vitro data, our in vivo study indicated that HNC0014 significantly attenuated the proliferation and overcame CDDP resistance; HNC0014 treatment was also accompanied by reduced c-Met, c-Metp, CD44, β-catenin, STAT3, and STAT3p, while increased tumor apoptosis was evident by higher expressions of PARP, caspase-3, and their cleaved forms (c_PARP and c_Cas 3).